Skye Bioscience, Inc.SKYENASDAQ
LOADING
|||
Year-over-year operating income growth rate
| Period | Value |
|---|---|
| Q3 2025 | 27.29% |
| Q2 2025 | -55.14% |
| Q1 2025 | -10.25% |
| Q4 2024 | -114.66% |
| Q3 2024 | 40.89% |
| Q2 2024 | -36.63% |
| Q1 2024 | -50.56% |
| Q4 2023 | 83.46% |
| Q3 2023 | -769.00% |
| Q2 2023 | 8.30% |
| Q1 2023 | 66.60% |
| Q4 2022 | -217.67% |
| Q3 2022 | 9.20% |
| Q2 2022 | -11.44% |
| Q1 2022 | -17.32% |
| Q4 2021 | -35.32% |
| Q3 2021 | 0.58% |
| Q2 2021 | -5.32% |
| Q1 2021 | -31.72% |
| Q4 2020 | 14.26% |
| Q3 2020 | -26.02% |
| Q2 2020 | 44.80% |
| Q1 2020 | -19.95% |
| Q4 2019 | -22.66% |
| Q3 2019 | 15.13% |
| Q2 2019 | -16.90% |
| Q1 2019 | -15.21% |
| Q4 2018 | -25.72% |
| Q3 2018 | 3.15% |
| Q2 2018 | 13.67% |
| Q1 2018 | -26.75% |
| Q4 2017 | -29.53% |
| Q3 2017 | -4.24% |
| Q2 2017 | 47.03% |
| Q1 2017 | -51.33% |
| Q4 2016 | -6.52% |
| Q3 2016 | 42.23% |
| Q2 2016 | -21.48% |
| Q1 2016 | -5.72% |
| Q4 2015 | -28.79% |